MorphoSys Investor Relations Material
Latest events
Q4 2023
MorphoSys
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from MorphoSys AG
Access all reports
Segment Data
Access more data
Revenue by
Source
Royalties
Licenses, Milestones and Other
Product Sales
Expenses by
Financials
MorphoSys AG is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. It offers MOR101 for the treatment of acute lymphoblastic leukemia. The company was founded in 1992 and is headquartered in Planegg, Germany.
Key slides for MorphoSys AG
Corporate Presentation
MorphoSys AG
Q4 2023
MorphoSys AG
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
MOR
Country
🇩🇪 Germany